Cargando…

Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Patients with metabolic syndrome (MetS) have increased cardiovascular risk. Capsaicin (CAP) has been shown to reduce lipids, but efficacy for patients with MetS is unknown. METHODS: A systematic review was performed according to PRISMA guidelines, to compare the effects of CAP against a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhonghui, Qu, Hua, Lin, Gongyu, Shi, Dazhuo, Chen, Keji, Gao, Zhuye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923259/
https://www.ncbi.nlm.nih.gov/pubmed/35299764
http://dx.doi.org/10.3389/fnut.2022.812294
_version_ 1784669647726968832
author Jiang, Zhonghui
Qu, Hua
Lin, Gongyu
Shi, Dazhuo
Chen, Keji
Gao, Zhuye
author_facet Jiang, Zhonghui
Qu, Hua
Lin, Gongyu
Shi, Dazhuo
Chen, Keji
Gao, Zhuye
author_sort Jiang, Zhonghui
collection PubMed
description BACKGROUND: Patients with metabolic syndrome (MetS) have increased cardiovascular risk. Capsaicin (CAP) has been shown to reduce lipids, but efficacy for patients with MetS is unknown. METHODS: A systematic review was performed according to PRISMA guidelines, to compare the effects of CAP against a placebo. Differences in the weight mean difference (WMD) with 95% confidence intervals (95% CI) were then pooled using a random effects model. RESULTS: Nine randomized controlled trials including 461 patients were identified in the overall analysis. CAP significantly decreased total cholesterol (TC) (WMD = −0.48, 95% CI: −0.63 to −0.34, I(2)= 0.00%) and low-density lipoprotein cholesterol (LDL-C) (WMD = −0.23, 95% CI: −0.45 to −0.02, I(2) = 68.27%) among patients with MetS. No significant effects of CAP were found on triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C) (WMD = −0.40, 95% CI: −1.50 to 0.71, I(2) = 98.32%; WMD = −0.08, 95% CI: −0.21 to 0.04, I(2) = 86.06%). Subgroup analyses indicated that sex and intervention period were sources of heterogeneity. The results revealed that CAP decreased TG levels in women (WMD = −0.59, 95% CI: −1.07 to −0.10) and intervention period <12 weeks (WMD = −0.65; 95% CI: −1.10 to −0.20). And there was no potential publication bias according to funnel plot, Begg' test and Egger regression test. CONCLUSIONS: CAP supplementation is a promising approach to decreasing TC and LCL-C levels in patients with MetS. However, short-term (<12 weeks) use of CAP in women may also reduce TG levels. SYSTEMATIC REVIEW REGISTRATION: Identifier: CRD42021228032.
format Online
Article
Text
id pubmed-8923259
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89232592022-03-16 Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Jiang, Zhonghui Qu, Hua Lin, Gongyu Shi, Dazhuo Chen, Keji Gao, Zhuye Front Nutr Nutrition BACKGROUND: Patients with metabolic syndrome (MetS) have increased cardiovascular risk. Capsaicin (CAP) has been shown to reduce lipids, but efficacy for patients with MetS is unknown. METHODS: A systematic review was performed according to PRISMA guidelines, to compare the effects of CAP against a placebo. Differences in the weight mean difference (WMD) with 95% confidence intervals (95% CI) were then pooled using a random effects model. RESULTS: Nine randomized controlled trials including 461 patients were identified in the overall analysis. CAP significantly decreased total cholesterol (TC) (WMD = −0.48, 95% CI: −0.63 to −0.34, I(2)= 0.00%) and low-density lipoprotein cholesterol (LDL-C) (WMD = −0.23, 95% CI: −0.45 to −0.02, I(2) = 68.27%) among patients with MetS. No significant effects of CAP were found on triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C) (WMD = −0.40, 95% CI: −1.50 to 0.71, I(2) = 98.32%; WMD = −0.08, 95% CI: −0.21 to 0.04, I(2) = 86.06%). Subgroup analyses indicated that sex and intervention period were sources of heterogeneity. The results revealed that CAP decreased TG levels in women (WMD = −0.59, 95% CI: −1.07 to −0.10) and intervention period <12 weeks (WMD = −0.65; 95% CI: −1.10 to −0.20). And there was no potential publication bias according to funnel plot, Begg' test and Egger regression test. CONCLUSIONS: CAP supplementation is a promising approach to decreasing TC and LCL-C levels in patients with MetS. However, short-term (<12 weeks) use of CAP in women may also reduce TG levels. SYSTEMATIC REVIEW REGISTRATION: Identifier: CRD42021228032. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8923259/ /pubmed/35299764 http://dx.doi.org/10.3389/fnut.2022.812294 Text en Copyright © 2022 Jiang, Qu, Lin, Shi, Chen and Gao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Jiang, Zhonghui
Qu, Hua
Lin, Gongyu
Shi, Dazhuo
Chen, Keji
Gao, Zhuye
Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_fullStr Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_short Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_sort lipid-lowering efficacy of the capsaicin in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923259/
https://www.ncbi.nlm.nih.gov/pubmed/35299764
http://dx.doi.org/10.3389/fnut.2022.812294
work_keys_str_mv AT jiangzhonghui lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT quhua lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT lingongyu lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT shidazhuo lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chenkeji lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT gaozhuye lipidloweringefficacyofthecapsaicininpatientswithmetabolicsyndromeasystematicreviewandmetaanalysisofrandomizedcontrolledtrials